Survival on treatment with second-line biologic therapy: A cohort study comparing cycling and swap strategies

Rheumatology (United Kingdom)

Volumn 53, Issue 9, 2014, Pages 1664-1668

  Favalli, Ennio Giulio ^a   Biggioggero, Martina ^a,b   Marchesoni, Antonio ^a   Meroni, Pier Luigi ^a,b  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti TNF; Biologic agents; Cycling; Drug survival; Mechanism of action; Rheumatoid arthritis; Swap; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; DRUG EFFICACY; DRUG RETENTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84906833072     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu158     Document Type: Article

References (20)

1. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
2. Marchesoni A, Zaccara E, Gorla R et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009;1173:837-46.
3. Furst DE, Gaylis N, Bray V et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007;66:893-9.
4. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebocontrolled, phase III trial. Lancet 2009;374:210-21.
5. Caporali R, Sarzi-Puttini P, Atzeni F et al. Switching TNFalpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 2010;9:465-9.
6. Gomez-Reino JJ, Carmona L. BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a fouryear period. Arthritis Res Ther 2006;8:R29.
7. Emery P, Keystone EC, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis 2007;67:1516-23.
8. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
9. Genovese MC, Becker J-C, Schiff MH et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
10. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
11. Gayat E, Resche-Rigon M, Mary JY et al. Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm Stat 2012; 11:222-9.
12. Schoels M, Aletaha D, Smolen JS et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor a inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise metaanalysis. Ann Rheum Dis 2012;71:1303-8.
13. Gomez-Reino JJ, Maneiro JR, Ruiz J et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR study. Ann Rheum Dis 2012;71: 1861-4.
14. Finckh A, Ciurea A, Brulhart L et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
15. Soliman MM, Hyrich KL, Lunt M et al. Rituximab or a second anti-tumour necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumour necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2012;64:1108-15.
16. Yoshida K, Tokuda Y, Oshikawa H et al. An observational study of tocilizumab and TNF-a inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology 2011;50: 2093-9.
17. Hyrich KL, Lunt M, Watson KD et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
18. Blom M, Kievit W, Fransen J et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 2009;36:2171-7.
19. Leffers HC, Østergaard M, Glintborg B et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011; 70:1216-22.
20. Solau-Gervais E, Laxenaire N, Cortet B et al. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology 2006;45:1121-4.